Open AccessMinimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment
Author(s) -
Kim Steegen,
Leon Levin,
Denise Evans,
KarlGünter Technau,
Lucia Hans
Publication year - 2022
Publication title -
the pediatric infectious disease journal/the pediatric infectious disease journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 140
eISSN - 1532-0987
pISSN - 0891-3668
DOI - 10.1097/inf.0000000000003647
Subject(s) - lamivudine , abacavir , dolutegravir , zidovudine , regimen , medicine , reverse transcriptase inhibitor , virology , drug resistance , resistance mutation , pharmacology , reverse transcriptase , human immunodeficiency virus (hiv) , viral load , biology , virus , antiretroviral therapy , genetics , viral disease , hepatitis b virus , polymerase chain reaction , gene